Nadofaragene Firadenovec Showcases Sustained Responses in BCG-Unresponsive NMIBC

The intravesical gene therapy elicited durable remissions in a high percentage of patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer.

Related Keywords

Texas ,United States ,Houston ,Paris ,France General ,France ,Pierre Yves Berclaz ,Ferring Pharmaceuticals ,Fdad Is Co Burst Edition ,European Association Of Urology ,Department Of Urology ,Division Of Surgery ,University Of Texas Md Anderson Cancer Center ,Cancer Center ,Yves Berclaz ,Bacillus Calmette Gu ,European Association ,Burst Edition ,Bacillus Calmette Guerin ,Bcg Unresponsive ,Non Muscle Invasive Bladder Cancer ,Nadofaragene Firadenovec ,